Methyl galbanate, a novel inhibitor of nitric oxide production in mouse macrophage RAW264.7 cells.
It is well known that inflammation is associated with various neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. An inflammatory mediator, nitric oxide (NO), is produced by inducible NO synthase (iNOS) in microglia and seems to be one of the possible causes of neurodegeneration. Several natural and synthetic compounds which exert anti-inflammatory effects by inhibiting NO production have been reported to date. The aim of this work was to investigate whether any of the 6 terpenoid coumarins (methyl galbanate, galbanic acid, farnesiferol A, badrakemone, umbelliprenin, and aurapten) isolated from Ferula szowitsiana DC. have inhibitory activity against NO production in RAW264.7 mouse macrophage cells stimulated with lipopolysaccharide (LPS) and interferon-γ (IFN-γ). Of the 6 terpenoid coumarins tested, methyl galbanate significantly decreased NO production in LPS/IFN-γ-stimulated RAW264.7 cells. In the presence of methyl galbanate, LPS/IFN-γ-induced iNOS mRNA expression was significantly decreased to 52% of the level found with LPS/IFN-γ stimulation alone. Methyl galbanate slightly attenuated COX-2 mRNA expression. Using the RAW264.7-tsAM5NE co-culture system, we showed that methyl galbanate protected neuronally differentiated tsAM5NE cells from NO-induced cell death by inhibiting the production of NO. Our finding suggests that methyl galbanate may be useful for developing a new drug against neurodegenerative diseases.
Department of Analytical Neurobiology, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku, Nagoya 468-8503, Japan.
Susumu
S
Kohno
Tomiyasu
T
Murata
Ayumi
A
Sugiura
Chihiro
C
Ito
Mehrdad
M
Iranshahi
Kiyomi
K
Hikita
Norio
N
Kaneda
D000818:Animals; D015153:Blotting, Western; D002460:Cell Line; D003374:Coumarins / Q000737:chemistry* / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects* / Q000378:metabolism*; D051379:Mice; D015394:Molecular Structure; D009569:Nitric Oxide / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012717:Sesquiterpenes / Q000737:chemistry / Q000494:pharmacology; D013729:Terpenes / Q000737:chemistry* / Q000494:pharmacology*; D014468:Umbelliferones / Q000737:chemistry / Q000494:pharmacology
D003374:Coumarins; D008070:Lipopolysaccharides; D012717:Sesquiterpenes; D013729:Terpenes; D014468:Umbelliferones; D009569:Nitric Oxide; D007371:Interferon-gamma; C048972:galbanic acid; C105832:aurapten; C003744:umbelliprenin
Cardiovasc Res. 1999 Aug 15;43(3):532-41
10690325
Biochim Biophys Acta. 1999 Feb 9;1410(2):215-28
10076028
FEBS Lett. 1998 Jul 17;431(2):210-4
9708904
Med Res Rev. 2009 Sep;29(5):767-820
19378317
Eur J Neurosci. 2008 Jun;27(11):2783-802
18588525
Cell Death Differ. 2004 Apr;11(4):403-15
14752508
J Biol Chem. 1999 Oct 29;274(44):31559-64
10531359
Cell Mol Life Sci. 2008 Oct;65(19):2979-99
18516495
Cell. 2010 Mar 19;140(6):918-34
20303880
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):s11-6
18174453
Cell Biol Int. 2011 Apr;35(4):325-34
21029049
Planta Med. 2008 Feb;74(2):147-50
18240102
J Neurosci. 2005 Jul 6;25(27):6449-59
16000635
Neurochem Res. 2008 Dec;33(12):2416-26
18415676
J Thromb Haemost. 2009 Jul;7 Suppl 1:35-7
19630764
Biochem Biophys Res Commun. 1995 Jan 17;206(2):533-40
7530002
Br J Pharmacol. 1999 May;127(2):546-52
10385257
J Neurosci. 1999 Dec 1;19(23):10250-61
10575022
Phytochemistry. 2007 Feb;68(4):554-61
17196626